AstraZeneca PLC (AZN) Q2 FY2026 6-K Filings and Company Events

Filings that contain financial statements

• 6-K, accession 0001104659-26-086846, filed 27 July 2026: interim results for H1 and Q2 2026 (period ended 30 June 2026). It holds the condensed consolidated statement of comprehensive income for H1 2026 and for Q2 2026, the statement of financial position, the statement of changes in equity, the H1 2026 statement of cash flows, the net debt note, and reconciliations of reported to core measures. The Q2 2026 product sales analysis is marked unreviewed by the company.
• No other 6-K filed from 27 July 2026 through 5 October 2026 contains financial statements. They are press releases on clinical trials, approvals, financing, board and share-capital notices.

Interim results (6-K 0001104659-26-086846, 27 July 2026)

• H1 2026 Total Revenue was $30,672 million, up 9% as reported and 6% at constant exchange rates. Q2 2026 Total Revenue was $15,384 million, up 6% as reported and 5% at constant exchange rates.
• Reported EPS was $3.60 for H1 and $1.61 for Q2. Core EPS was $5.21 for H1 (up 12%) and $2.63 for Q2 (up 21%).
• Guidance for FY 2026 at constant exchange rates was reconfirmed: Total Revenue up by a mid-to-high single-digit percentage, Core EPS up by a low double-digit percentage, Core tax rate of 18-22%.
• The first interim dividend was raised by 3 cents to $1.06 per share (ex-dividend 6 August 2026 in London and Stockholm, 7 August 2026 on the NYSE; payment date 8 September 2026).
• The company said double-digit growth in Oncology and Rare Disease offset headwinds from the US loss of exclusivity of Farxiga and China volume-based procurement. It also reported that the CARDIO-TTRansform Phase III trial of Wainua in ATTR-CM did not meet its primary endpoint (July 2026) and reaffirmed its $80 billion Total Revenue ambition for 2030.

Capital actions and financing

• 25 August 2026, euro bond pricing (6-K 0001654954-26-007840): AstraZeneca Finance LLC, guaranteed by AstraZeneca PLC, priced four tranches of Eurobonds totalling EUR 2.55 billion ($2.97 billion): EUR 700 million ($816.55 million) at 3.402% due 1 March 2030; EUR 600 million ($699.9 million) at 3.652% due 1 September 2032; EUR 500 million ($583.25 million) at 3.923% due 1 September 2035; EUR 750 million ($874.88 million) at 4.169% due 1 September 2038. Proceeds are for general corporate purposes. The notes were priced on 24 August 2026 with closing expected 1 September 2026.
• 1 September 2026, notes admitted to trading (6-K 0001654954-26-007992): all four series were admitted to trading on the London Stock Exchange Main Market on 1 September 2026, under the EMTN programme.
• Routine total voting rights and further-securities admission notices were filed on 3 August, 1 September and 1 October 2026 (accessions 0001654954-26-007166, -007169, -008040, -008042, -008739, -008741).

Deals and collaborations

• Zegfrovy (sunvozertinib), closed 1 September 2026 (6-K 0001654954-26-007986): AstraZeneca announced it completed the previously announced exclusive global license from Dizal Pharmaceutical and has acquired worldwide rights to develop and commercialise the oral EGFR inhibitor. It pays $600 million upfront, up to $900 million in development, regulatory and sales milestones, and tiered royalties. The company said the transaction does not affect its 2026 guidance. The agreement was first disclosed in the 27 July 2026 interim results (July 2026 signing). US launch is planned for Q4 2026 for the 2nd-line indication.
• Sino Biopharmaceutical licence of TQC3721, signed July 2026, not reported closed (6-K 0001104659-26-086846, 27 July 2026): in July 2026 AstraZeneca and Chia Tai Tianqing Pharmaceutical Group (CTTQ), a subsidiary of Sino Biopharmaceutical Limited, entered into an exclusive licence for the development, manufacturing and commercialisation of CTTQ's PDE3/4 inhibitor TQC3721 for respiratory indications. Sino Biopharmaceutical is eligible for a $200 million upfront payment, up to $1.9 billion in development, regulatory and sales milestones, and tiered royalties up to double-digit percentages. The filing says the agreement is subject to customary closing conditions, including regulatory clearances; no 6-K filed through 5 October 2026 reports completion.
• Summit Therapeutics equity investment, signed 29 September 2026, closed 5 October 2026:
  • 6-K 0001654954-26-008615 (29 September): AstraZeneca agreed to invest $2 billion in newly issued convertible preferred stock of Summit, giving rights equivalent to about 12.0% of Summit's outstanding common stock (about 10.6% fully diluted). The two companies also signed a clinical collaboration to test sonesitatug vedotin with Summit's ivonescimab, with each party contributing its medicine and sharing trial costs, and a memorandum of understanding toward a broader development programme.
  • 6-K 0001654954-26-008760 (2 October): AstraZeneca and Daiichi Sankyo signed a clinical collaboration with Summit to test Datroway with ivonescimab, starting with a Phase III trial in 1st-line triple-negative breast cancer.
  • 6-K 0001654954-26-008783 (5 October): AstraZeneca announced it completed the $2 billion equity investment.

Board

• 1 September 2026 (6-K 0001654954-26-007988): Wan Ling Martello was appointed Non-Executive Director effective 1 September 2026 and joins the Audit Committee.

Pipeline readouts and setbacks

• 27 July 2026, Sone-Ve (6-K 0001654954-26-006895): the CLARITY-Gastric01 Phase III trial showed a statistically significant overall survival improvement in 2nd and later-line CLDN18.2-positive gastric cancers. The progression-free survival endpoint in the 2nd and later-line population showed a trend but was not statistically significant.
• 27 July 2026, Ultomiris (6-K 0001654954-26-006897): the adult and adolescent Phase III trial in HSCT-TMA missed its primary event-free survival endpoint. Filings are being advanced for paediatric patients.
• 17 August 2026 (6-K 0001654954-26-007679): the eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in 1st-line metastatic NSCLC was discontinued on an independent committee recommendation, which judged it unlikely to meet its primary endpoints. Other volrustomig Phase III trials continue.
• 17 August 2026 (6-K 0001654954-26-007677, -007681): positive Phase III results for Tagrisso plus Orpathys (SAFFRON, progression-free and overall survival) and for Enhertu in 1st-line HER2-mutant NSCLC (DESTINY-Lung04, progression-free survival).
• 27 August 2026 (6-K 0001654954-26-007894): Tezspire met its co-primary endpoints in the Phase III CROSSING trial in eosinophilic esophagitis.
• 1 September 2026 (6-K 0001654954-26-007983): Tagrisso plus Orpathys showed a significant progression-free survival improvement in 1st-line EGFR-mutated lung cancer.
• 8 September 2026 (6-K 0001654954-26-008172): Imfinzi plus Imdelltra showed a significant overall survival improvement in 1st-line extensive-stage small cell lung cancer (DeLLphi-305 interim analysis).
• 14 September 2026 (6-K 0001654954-26-008323): the SERENA-4 Phase III trial of Etcamah plus palbociclib did not meet its progression-free survival primary endpoint, though a numerical improvement was seen.

Regulatory approvals and opinions

• 31 July 2026: Datroway approved in the EU for 1st-line metastatic triple-negative breast cancer (0001654954-26-007050).
• 1 September 2026: Enhertu plus pertuzumab approved in the EU for 1st-line HER2-positive metastatic breast cancer (0001654954-26-007990).
• 7 September 2026 (filed 8 September): Etcamah plus a CDK4/6 inhibitor granted US accelerated approval for HR-positive breast cancer with an emergent ESR1 mutation, based on SERENA-6 (0001654954-26-008150).
• 21 September 2026: positive EU committee opinions for Enhertu in early breast cancer (0001654954-26-008476) and Klygefa (0001654954-26-008478).
• 23 September 2026: Trixeo approved in the EU for asthma (0001654954-26-008520).

Not material

Director/PDMR shareholding notices (19 August; 15 and 18 September 2026) are routine dealing notifications (accessions 0001654954-26-007742, -008367, -008369, -008438).